NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2000, the company has made significant strides in developing innovative anti-infective products, particularly in the fields of ophthalmology and dermatology. With a focus on its proprietary Avenova® solution, NovaBay offers unique antimicrobial treatments that stand out for their effectiveness and safety profile. The company has established a strong market position, recognised for its commitment to addressing unmet medical needs through advanced science. Over the years, NovaBay has achieved notable milestones, including successful product launches and strategic partnerships, solidifying its reputation as a leader in the development of novel therapies.
DitchCarbon Score
How does NovaBay Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
NovaBay Pharmaceuticals, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
NovaBay Pharmaceuticals, Inc.'s reported carbon emissions
NovaBay Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that NovaBay may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction strategies. However, without specific emissions data or commitments, it is challenging to assess NovaBay's position relative to its peers in terms of climate action. As the industry evolves, it will be important for NovaBay to consider developing and communicating its climate commitments to align with broader environmental goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
NovaBay Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
